Table 1 Active-controlled trials
From: Treatment of established postoperative nausea and vomiting: a quantitative systematic review
Ref | Validity score | Comparison | Surgery | Sponsorship |
|---|---|---|---|---|
| Â | random blinding dropouts | (number of patients in brackets) | Â | Â |
[28] | 1/1/0 | 1) Ondansetron 8 mg iv (50) 2) Droperidol 1.25 mg iv (50) | Not reported | Â |
[29] | 2/2/1 | 1) Ondansetron 0.1 mg/kg iv (16) 2) Droperidol 20 μg/kg iv (13) | Extraabdominal |  |
[32] | 2/2/0 | 1) Droperidol 1.25 mg iv (27) 2) Metoclopramide 10 mg iv (25) 3) Propofol 10 mg iv (26) | Mixed | Â |
[36] | 1/1/0 | 1) Ondansetron 4 mg iv (380) 2) Metoclopramide 10 mg iv (366) | Not reported | Glaxo |
[37] | 1/1/0 | 1) Droperidol 20 μg/kg iv (40) 2) Granisetron 40 μg/kg iv (40) 3) Metoclopramide 0.2 mg/kg iv (40) | Laparoscopic cholecystectomy |  |
[38] | 1/1/0 | 1) Droperidol 20 μg/kg iv (40) 2) Granisetron 40 μg/kg iv (40) 3) Metoclopramide 0.2 mg/kg iv (40) | Major gynecological |  |
[39] | 1/1/1 | 1) Alizapride 100 mg iv (24) 2) Droperidol 1 mg iv (25) 3) Ondansetron 8 mg iv (25) | Gynecological | Glaxo |